Next Article in Journal
Impaired Platelet Aggregation and Rebalanced Hemostasis in Patients with Chronic Hepatitis C Virus Infection
Next Article in Special Issue
Chloramidine/Bisindolylmaleimide-I-Mediated Inhibition of Exosome and Microvesicle Release and Enhanced Efficacy of Cancer Chemotherapy
Previous Article in Journal
Atractylenolide-I Protects Human SH-SY5Y Cells from 1-Methyl-4-Phenylpyridinium-Induced Apoptotic Cell Death
Previous Article in Special Issue
Pathogenic or Therapeutic Extracellular Vesicles in Rheumatic Diseases: Role of Mesenchymal Stem Cell-Derived Vesicles

Imipramine Protects against Bone Loss by Inhibition of Osteoblast-Derived Microvesicles

Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, Jiangsu, China
Wuxi Second People’s Hospital of Nanjing Medical University, Wuxi 214123, Jiangsu, China
Wuxi Medical School, Jiangnan University, Wux i214122, Jiangsu, China
Authors to whom correspondence should be addressed.
Academic Editors: Thomas Ritter, Matthew Griffin and Aideen Ryan
Int. J. Mol. Sci. 2017, 18(5), 1013;
Received: 8 March 2017 / Revised: 2 April 2017 / Accepted: 3 May 2017 / Published: 8 May 2017
The maintenance of bone homeostasis is largely dependent upon cellular communication between osteoclasts and osteoblasts. Microvesicles (MVs) represent a novel mechanism for osteoblasts and osteoclasts communication, as has been demonstrated in our previous study. Sphingomyelinases catalyze the hydrolysis of sphingomyelin, which leads to increased membrane fluidity and facilitates MV generation. This effect can be inhibited by imipramine, an inhibitor of acid sphingomyelinase (ASM), which is also known as a member of tricyclic antidepressants (TCAs). A recent study has reported that in vitro treatment of imipramine blocked MVs release from glial cells. However, whether imipramine has this effect on osteoblast-derived MVs and whether it is involved in MV generation in vivo is unclear. Here, our investigations found that imipramine slightly reduced the expression of osteoblast differentiation of related genes, but did not impact parathyroid hormone (PTH) regulation for these genes and also did not affect receptor activator of nuclear factor-κB ligand (RANKL)-mediated osteoclast formation; however, imipramine treatment blocked MVs released from osteoblasts and inhibited MV-induced osteoclast formation. In vivo, mice administrated with imipramine were protected from ovariectomy-induced bone loss as evaluated by various bone structural parameters and serum levels of biochemical markers. Our results suggest that inhibiting the production of MVs containing RANKL in vivo is very important for preventing bone loss. View Full-Text
Keywords: imipramine; microvesicles; cellular communication; bone loss imipramine; microvesicles; cellular communication; bone loss
Show Figures

Graphical abstract

MDPI and ACS Style

Deng, L.; Peng, Y.; Jiang, Y.; Wu, Y.; Ding, Y.; Wang, Y.; Xu, D.; Fu, Q. Imipramine Protects against Bone Loss by Inhibition of Osteoblast-Derived Microvesicles. Int. J. Mol. Sci. 2017, 18, 1013.

AMA Style

Deng L, Peng Y, Jiang Y, Wu Y, Ding Y, Wang Y, Xu D, Fu Q. Imipramine Protects against Bone Loss by Inhibition of Osteoblast-Derived Microvesicles. International Journal of Molecular Sciences. 2017; 18(5):1013.

Chicago/Turabian Style

Deng, Lili, Ying Peng, Yuhai Jiang, Yu Wu, Yuedi Ding, Yaping Wang, Dong Xu, and Qiang Fu. 2017. "Imipramine Protects against Bone Loss by Inhibition of Osteoblast-Derived Microvesicles" International Journal of Molecular Sciences 18, no. 5: 1013.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop